Research institution
Cancer Institute and Hospital, Chinese Academy of Medical Sciences Clinical Trials
Studies where Cancer Institute and Hospital, Chinese Academy of Medical Sciences is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 235High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
This is a prospective, randomized, controlled Phase II clinical study designed to evaluate the efficacy and safety of adding Aitua Combination Antibody (a PD-1/CTLA-4 bispecific antibody) to standard neoadjuvant chemotherapy for…
- Conditions
- High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- NCT07432594
- Testing
- Aitua Combination Antibody, Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin (AUC 5)
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Diffuse Large B-Cell Lymphoma (DLBCL)
Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma
Background: The central nervous system (CNS) recurrence rate of patients with high-risk diffuse large B-cell lymphoma (DLBCL) is as high as 15% - 20%, and the prognosis is extremely poor once it occurs.
- Trial name
- NCT07917624
- Testing
- Lenalidomide, Bruton's tyrosine kinase inhibitor, Chidamide
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Renal Cell Carcinoma (Kidney Cancer), Clear Cell Renal Cell Carcinoma
Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma
This is a prospective, open, multi-cohort phase II study The study included a screening period (participants signed informed consent no more than 28 days before the first treatment in the study), a treatment period (treatment…
- Trial name
- NCT07909265
- Testing
- Cadonilimab,Lenvatinib
- Where
- China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Head and Neck Squamous Cell Carcinoma
Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Study
This is a prospective, single-arm, phase II study. It aims to evaluate whether neoadjuvant targeted therapy combined with immunotherapy and chemotherapy is effective and safe in patients with locally advanced, resectable head and…
- Trial name
- NCT07906587
- Testing
- Combining nimotuzumab and toripalimab with nab-paclitaxel plus cisplatin
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer (CRC)
Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study
This phase II, single-arm clinical study aims to evaluate the efficacy and safety of toripalimab combined with cetuximab and irinotecan as second-line treatment for patients with advanced right-sided colon cancer with wild-type…
- Trial name
- NCT07896681
- Testing
- Toripalimab, Cetuximab, Irinotecan
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Biliary Tract Cancer (BTC), Surgery
Phase II Study of Primary Tumor Resection and Selective Lymph Node Dissection Followed by RT for BTC With Lymph Node Metastases
This is a multicenter, open-label, single-arm, prospective phase II clinical study. Eligible patients with lymph node-positive biliary tract cancer will undergo primary tumor resection with selective lymph node dissection.
- Conditions
- Biliary Tract Cancer (BTC), Surgery, Radiotherapy
- Trial name
- NCT07893392
- Testing
- Primary Tumor Resection and Selective Lymph Node Dissection, Postoperative Radiotherapy, Capecitabine or S-1
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Lung Cancer, Lung Metastasis
mRNA Vaccine for Advanced Lung Cancer and Pulmonary Metastases of Solid Tumors
BMD006 is an off-the-shelf antitumor mRNA vaccine targeting lung cancer and lung metastatic solid tumors. This is a single-center, open-label, dose-escalation clinical trial.
- Trial name
- NCT06928922
- Testing
- BMD006 monotherapy, BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Escalation), BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Expansion)
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer Metastatic to Liver
The QL1706 Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potentially Resectable Colorectal Cancer Patients With Liver Metastases
The goal of this clinical trial is to learn if QL1706 (Iparomlimab/ Tuvonralimab)+ chemotherapy+ cetuximab/bevacizumab works to treat potentially resectable colorectal cancer patients with liver metastases in adults.
- Trial name
- NCT07863869
- Testing
- Arm A, Arm B
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
The goal of this clinical trial is to learn if Trastuzumab Rezetecan (SHR-A1811) is safe and tolerable for patients with HER2-Low unresectable/metastatic breast cancer complicated with visceral crisis.
- Trial name
- NCT07203729
- Testing
- Trastuzumab Rezetecan, Chemotherapy of Physician's Choice
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Small-cell Lung Cancer, Brain Metastases
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
This phase III trial compares the effect of stereotactic radiosurgery and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the…
- Conditions
- Small-cell Lung Cancer, Brain Metastases, SRS, Stereotactic Radiotherapy
- Trial name
- SHARP (NCT06457906)
- Testing
- Experimental group (SRS/SRT/Hypo-RT), Controled group (HA-WBRT)
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Completed, with results posted
All 1Hepatocellular Carcinoma, Malignant Neoplasm
Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection
The purpose of this study is to assess the efficacy and safety of combining autologous Tcm immunotherapy and TACE in HCC patients with MVI after radical resection.
- Trial name
- NCT03575806
- Testing
- TACE plus autologous Tcm immunotherapy, TACE
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences